{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T09:25:45Z","timestamp":1787995545638,"version":"build-2784847793"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.urology.2023.01.024","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T21:34:57Z","timestamp":1675287297000},"page":"7-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Real-World Comparative Safety and Effectiveness of\u00a0Irreversible Electroporation and High-Intensity Focused Ultrasound for\u00a0Prostate Cancer Ablation"],"prefix":"10.1016","volume":"174","author":[{"given":"Kristen A.","family":"Cribbs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth F.","family":"Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy J.","family":"Lahue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Polascik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2023.01.024_bib0001","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamasurg.2021.3181","article-title":"A focus on focal therapy for prostate cancer","volume":"156","author":"Lebastchi","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.urology.2023.01.024_bib0002","doi-asserted-by":"crossref","first-page":"e13789","DOI":"10.1111\/and.13789","article-title":"A systematic review of irreversible electroporation in localised prostate cancer treatment","volume":"52","author":"Morozov","year":"2020","journal-title":"Andrologia"},{"key":"10.1016\/j.urology.2023.01.024_bib0003","unstructured":"US Food and Drug Administration (FDA). 510(K) Premarket Notification - NanoKnife System - No. K183385. 2019. Accessed 15 July 2022. Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/pmn.cfm?ID=K183385."},{"key":"10.1016\/j.urology.2023.01.024_bib0004","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.juro.2017.03.137","article-title":"Partial gland treatment of prostate cancer using high-intensity focused ultrasound in the primary and salvage settings: a systematic review","volume":"198","author":"Golan","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2023.01.024_bib0005","unstructured":"US Food and Drug Administration (FDA). Device Classification Under Section 513(f)(2)(De Novo). High Intensity Ultrasound for Prostate Tissue Ablation - DEN150011. 2015."},{"key":"10.1016\/j.urology.2023.01.024_bib0006","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5489\/cuaj.870","article-title":"High-intensity focused ultrasound for prostate cancer: a practice guideline","volume":"4","author":"Lukka","year":"2010","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.urology.2023.01.024_bib0007","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.euf.2015.04.006","article-title":"Systematic review of the efficacy and safety of high-intensity focused ultrasound for localised prostate cancer","volume":"1","author":"Veereman","year":"2015","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urology.2023.01.024_bib0008","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.urology.2023.01.024_bib0009","unstructured":"Higgins J, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions. 2021. Accessed 3 August 2021. Available at: https:\/\/training.cochrane.org\/handbook."},{"key":"10.1016\/j.urology.2023.01.024_bib0010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.urology.2023.01.024_bib0011","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/bju.13991","article-title":"Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer","volume":"120","author":"Scheltema","year":"2017","journal-title":"BJU Int"},{"issue":"3 Part 1","key":"10.1016\/j.urology.2023.01.024_bib0012","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.juro.2016.09.091","article-title":"Nanoknife electroporation ablation trial: a prospective development study investigating focal irreversible electroporation for localized prostate cancer","volume":"197","author":"Valerio","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2023.01.024_bib0013","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/pcan.2015.47","article-title":"Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control","volume":"19","author":"Ting","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urology.2023.01.024_bib0014","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.purol.2019.06.004","article-title":"Salvage hemiablation high intensity focused ultrasound for unilateral radio-recurrent prostate cancer","volume":"29","author":"Aoun","year":"2019","journal-title":"Prog Urol"},{"key":"10.1016\/j.urology.2023.01.024_bib0015","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2016.09.039","article-title":"Focal high intensity focused ultrasound of unilateral localized prostate cancer: a prospective multicentric hemiablation study of 111 patients","volume":"71","author":"Rischmann","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2023.01.024_bib0016","doi-asserted-by":"crossref","first-page":"e836","DOI":"10.1016\/S1569-9056(16)15102-4","article-title":"836 MRI-US fusion guided high-intensity focused ultrasound with Focal-One\u00ae system: impact on PSA, complications and genito-urinary functions during initial experience","volume":"15","author":"Barret","year":"2016","journal-title":"Eur Urol"},{"issue":"4S","key":"10.1016\/j.urology.2023.01.024_bib0017","doi-asserted-by":"crossref","first-page":"e939","DOI":"10.1016\/j.juro.2017.02.2287","article-title":"Medium term outcomes following focal HIFU for the treatment of localised prostate cancer: a single centre experience","volume":"197","author":"Mistry","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2023.01.024_bib0018","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/JU.0000000000000506","article-title":"Focal therapy for localized prostate cancer with either high intensity focused ultrasound or cryoablation: a single institution experience","volume":"203","author":"Tourinho-Barbosa","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2023.01.024_bib0019","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.juro.2016.06.092","article-title":"Pathological, oncologic and functional outcomes of a prospective registry of salvage high intensity focused ultrasound ablation for radiorecurrent prostate cancer","volume":"197","author":"Siddiqui","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2023.01.024_bib0020","first-page":"93","article-title":"High intensity focused ultrasound as first line salvage therapy in prostate cancer local relapse after radical prostatectomy: 4-year follow-up outcomes","volume":"69","author":"Palermo","year":"2017","journal-title":"Minerva Urol Nefrol"},{"key":"10.1016\/j.urology.2023.01.024_bib0021","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.juro.2017.06.078","article-title":"High intensity focused ultrasound for radiorecurrent prostate cancer: a North American clinical trial","volume":"199","author":"Jones","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2023.01.024_bib0022","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.prnil.2019.12.002","article-title":"Survival and quality of life outcomes of high-intensity focused ultrasound treatment of localized prostate cancer","volume":"8","author":"Royce","year":"2020","journal-title":"Prostate Int"},{"key":"10.1016\/j.urology.2023.01.024_bib0023","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/CH-168125","article-title":"Percutaneous irreversible electroporation (IRE) of prostate cancer: contrast-enhanced ultrasound (CEUS) findings during follow up","volume":"64","author":"Beyer","year":"2016","journal-title":"Clin Hemorheol Microcirc"},{"key":"10.1016\/j.urology.2023.01.024_bib0024","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.juro.2016.02.2986","article-title":"Pilot study to assess safety and clinical outcomes of irreversible electroporation for partial gland ablation in men with prostate cancer","volume":"196","author":"Murray","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2023.01.024_bib0025","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1007\/s10147-020-01723-9","volume":"25","author":"Shoji","year":"2020","journal-title":"Int J Clin Oncol"},{"issue":"Suppl4","key":"10.1016\/j.urology.2023.01.024_bib0026","first-page":"e611","article-title":"Clinical predictors for detection of significant cancer in follow-up biopsy after focal therapy with high-intensity focused ultrasound for localized prostate cancer: a multi-institutional study","volume":"203","author":"Shoji","year":"2020","journal-title":"J Urology"},{"key":"10.1016\/j.urology.2023.01.024_bib0027","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.2018.3712","article-title":"Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force","volume":"319","author":"Fenton","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2023.01.024_bib0028","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/1748-717X-8-256","article-title":"Potency preservation following stereotactic body radiation therapy for prostate cancer","volume":"8","author":"Obayomi-Davies","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.urology.2023.01.024_bib0029","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/jnci\/djh259","article-title":"Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study","volume":"96","author":"Potosky","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2023.01.024_bib0030","unstructured":"US Food and Drug Administration (FDA). Clinical investigations for prostate tissue ablation devices: guidance for industry and Food and Drug Administration staff. 2020. Accessed 15 July 2022. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-investigations-prostate-tissue-ablation-devices."}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429523000717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429523000717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:00:06Z","timestamp":1758769206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429523000717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":30,"alternative-id":["S0090429523000717"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2023.01.024","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Comparative Safety and Effectiveness of\u00a0Irreversible Electroporation and High-Intensity Focused Ultrasound for\u00a0Prostate Cancer Ablation","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2023.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}